BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 24, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 17, 2011
View Archived Issues
Results disclosed from three phase I trials of darexaban
Read More
AstraZeneca begins phase III clinical program for NKTR-118
Read More
Inhibition of rRNA synthesis by CX-5461, a promising therapeutic strategy for cancer
Read More
Genomic rearrangements associated with transcriptional control implicated in prostate tumorigenesis
Read More
NO-releasing nanoparticles protect from hypovolemic shock effects
Read More
LEAD identifies novel Notch-sparing gamma-secretase inhibitors
Read More
New cannabinoid receptor modulators presented by Arena for pain
Read More
iTherX begins phase Ib study of ITX-5061 in HCV-infected liver transplant recipients
Read More
Array BioPharma and Genentech patent new B-raf inhibitors for cancer
Read More
Merck & Co. presents new muscarinic M1 receptor positive allosteric modulators
Read More
Merck & Co. patents novel beta3-adrenoceptor agonists for urinary disorders
Read More
Amylin and Takeda suspend pramlintide/metreleptin trial in obesity
Read More
RegeneRx's phase II RGN-352 trial in acute myocardial infarction on clinical hold
Read More
Nymox presents data from long-term NX-1207 trial in benign prostatic hyperplasia
Read More
Genfit and sanofi-aventis sign new agreement to develop drugs for metabolic disorders
Read More
Epistem and sanofi-aventis enter oncology biomarker collaboration
Read More
PsiOxus begins phase II study of MT-102 in cachexia
Read More
Human Genome Sciences acquires rights to anticancer drug FP-1039 from FivePrime
Read More
Athersys doses first patient in phase II trial of allogeneic cell therapy product MultiStem
Read More
Cortex regains all Ampakine assets and rights for respiratory depression
Read More
Cardiotrophin-1 enters phase I trial in Spain
Read More
Biotron completes first half of phase II trial of BIT-225 in HCV
Read More
Cytavis begins recruitment in Austria for phase II trial of CY-503 in colorectal carcinoma
Read More
Phosphagenics receives commitments for money to fund clinical trials and product rollouts
Read More
